The Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis

Summary

The purpose of this study is to evaluate efficacy of Chinese medicine treatment for chronic atrophic gastritis. It is a multi-center, randomized, placebo-controlled trial.

Conditions

• Chronic Atrophic Gastritis

Interventions

DRUG

Talcid®

Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.

DRUG

Chinese medicine prescription

The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.

DRUG

Placebo

The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.

DRUG

Compound Azimtamide Entieric-coated Tablets

Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.

Sponsors & Collaborators

• Beijing University of Chinese Medicine

  collaborator OTHER

• Xiyuan Hospital of China Academy of Chinese Medical Sciences

  collaborator OTHER

• Shaanxi Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Gansu Provincial Hospital

  collaborator OTHER

• Tianjin Nankai Hospital

  collaborator OTHER

• The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

  collaborator OTHER

• Guangdong Provincial Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Hebei Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

  collaborator UNKNOWN

• Shanxi Province hospital Research Institute of Traditional Chinese Medicine

  collaborator UNKNOWN

• Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

  collaborator OTHER

• Shanghai University of Traditional Chinese Medicine

  collaborator OTHER

• China-Japan Friendship Hospital

  collaborator OTHER

• Wangjing Hospital, China Academy of Chinese Medical Sciences

  lead OTHER

Principal Investigators

• Wei Wei, Ph.D · Wangjing Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-12

Primary Completion

2021-05-01

Completion

2021-11-30

Countries

• China

Study Locations